While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Susan Green developed a stubborn ...

Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.

From early failures to prefusion F protein breakthroughs, RSV vaccine development has accelerated, reshaping prevention ...

Although lack of routine testing and limitations to current diagnostic testing likely lead to underreporting of respiratory syncytial virus, RSV still poses a substantial economic burden. Respiratory ...

Please provide your email address to receive an email when new articles are posted on . The proportion of respiratory infections testing positive for RSV among pregnant people ranged from 0.9% to 10.7 ...

The implementation of universal nirsevimab prophylaxis was associated with significantly lower respiratory syncytial virus (RSV) positivity and reduced disease severity, including shorter hospital ...

Residents of homeless shelters were tested for respiratory syncytial virus (RSV) and influenza, which were found to have similar prevalence in the population. People experiencing homelessness (PEH) ...

Respiratory syncytial virus (RSV) vaccines recently approved for people 60 and older would dramatically reduce the disease's significant burden of illness and death in the United States if they were ...